Nuvectis Pharma, Inc. (NVCT) — Financial statements
Income statement, balance sheet, and cash flow for Nuvectis Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 18↑40.5% | 13↓16.0% | 15↑16.3% | 13↑38.6% | 10 | |
| General & Administrative Expenses | 9↑36.0% | 7↓7.8% | 8↑25.1% | 6↑79.4% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑36.0% | 7↓7.8% | 8↑25.1% | 6↑79.4% | 3 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 28↑38.9% | 20↓13.3% | 23↑19.0% | 19↑49.2% | 13 | |
| Total Costs & Expenses | 28↑38.9% | 20↓13.3% | 23↑19.0% | 19↑49.2% | 13 | |
| Operating Results | ||||||
| Operating Income | -28↓38.9% | -20↑13.3% | -23↓19.0% | -19↓49.2% | -13 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -28↓45.1% | -19↑17.0% | -23↓19.0% | -19↓49.2% | -13 | |
| EBIT | -28↓45.1% | -19↑17.0% | -23↓19.0% | -19↓49.2% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↑33.6% | 0.85↑33.0% | 0.64↑327.5% | 0.15↑3625.0% | 0.00 | |
| Interest Income | 1↑33.6% | 0.85↑33.0% | 0.64↑327.5% | 0.15↑3625.0% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.85 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 1↑33.6% | 0.85↑33.0% | 0.64↑327.5% | 0.15↑3625.0% | 0.00 | |
| Income Before Tax | -26↓39.2% | -19↑14.6% | -22↓16.6% | -19↓48.1% | -13 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -26↓39.2% | -19↑14.6% | -22↓16.6% | -19↓48.1% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -26↓39.2% | -19↑14.6% | -22↓16.6% | -19↓48.1% | -13 | |
| Bottom-Line Net Income | -29↓52.0% | -19↑14.6% | -22↓16.6% | -19↓48.1% | -13 | |
| EPS (Basic) | -1.32↓18.9% | -1.11↑22.4% | -1.43↑5.3% | -1.51↓38.5% | -1.09 | |
| EPS (Diluted) | -1.32↓18.9% | -1.11↑22.4% | -1.43↑5.3% | -1.51↓38.5% | -1.09 | |
| Weighted Average Shares | 22↑27.5% | 17↑10.0% | 16↑22.9% | 13↓0.5% | 13 | |
| Weighted Average Diluted Shares | 22↑27.5% | 17↑10.0% | 16↑22.9% | 13↓0.5% | 13 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.